Lilly to supply 300,000 vials of COVID-19 monoclonal antibody to the U.S.
Eli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreEli Lilly and Company officially announced on Oct. 28, an initial deal with the U.S. government to supply 300,000 vials
Read moreEli Lilly and Company revealed on Monday, new efficiency and safety results from the Phase 2 SERENITY trial assessing Mirikizumab
Read moreEnzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read moreJanssen’s Golimumab, a human monoclonal antibody used as an immunosuppressive drug and sold under the brand name Simponi, has received
Read moreSwiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read moreEli Lilly and Company announced the start of BLAZE-2, a Phase 3 study of the monoclonal antibody LY-CoV555 vaccine candidate
Read moreHarbour BioMed, a global clinical stage biopharmaceutical company developing novel therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19,
Read moreAbbVie, Harbour BioMed, Utrecht University and the Erasmus Medical Center (EMC) revealed today they have entered into a partnership to
Read moreScientists at clinical-stage biopharmaceutical company Harbour BioMed (HBM), Utrecht University and Erasmus Medical Center announced that they have discovered a
Read moreNew post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more